Company Profile
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
Latest News
PINK vs. XLV: How Do These Two Health Care ETFs Match Up?
Liquidia vs. United Therapeutics: Which PAH Stock Is the Better Buy Now?
Should Vanguard S&P Mid-Cap 400 Growth Index Fund ETF Shares (IVOG) Be on Your Investing Radar?
Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Website | https://www.unither.com |
| Audit Risk | 3 |
| Board Risk | 5 |
| Overall Risk | 3 |
| Market Cap | 26.32B |
| Trailing P/E | 19.54 |
| Forward P/E | 16 |
| Trailing Annual Div. Rate | 0 |
| Trailing Annual Div. Yield | 0.00% |
| Trailing EPS | 27.05 |
| Forward EPS | 33.03 |
| Book Value | 139.98 |
| Price-to-Book | 3.78 |
| Enterprise-to-Revenue | 6.4 |
| Enterprise-to-EBITDA | 13.1 |
| Short Ratio | 3.81 |
| Earnings Date | 08/05/2026 |
| Earnings Call Date | 08/05/2026 |
| Earnings Average | 7.03 |
| Earnings Low | 6.07 |
| Earnings High | 8.59 |
| Revenue Average | 804.65M |
| Revenue Low | 783.00M |
| Revenue High | 834.00M |